Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03886077 · ClinicalTrials.gov registry record
Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
A clinical trial of Coronary Artery Disease and Morality, sponsored by Sentara Norfolk General Hospital.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT03886077 is a study of Coronary Artery Disease and Morality that is actively recruiting participants, run by Sentara Norfolk General Hospital. The registered enrollment target is 50 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03886077, a study of Coronary Artery Disease and Morality, is actively recruiting participants, sponsored by Sentara Norfolk General Hospital.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, non-blinded cohort study that will assess the safety, tolerability, and antiviral efficacy of glecaprevir/pibrentasivir therapy given post-discharge to HCV-negative recipients of HCV infected donors. Patients who meet entry criteria will be enrolled while on the transplant waitlist. At the time of transplant, some donors will be HCV positive / NAT positive and some will not be infected. Enrolled patients who receive an HCV negative donor will serve as contemporaneous controls. All study subjects who receive an HCV positive organ will be confirmed to have acquired HCV infection and genotype will be assessed prior to treatment with therapy.
Conditions Studied
Interventions
- DRUG glecaprevir/pibrentasivir
Study Locations (1)
Virginia
- Sentara Norfolk General Hospital - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03886077
The ClinicalTrials.gov registry entry for NCT03886077 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (96% lower). The listed sponsor is Sentara Norfolk General Hospital, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which glecaprevir/pibrentasivir is the first listed.
NCT03886077 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03886077 about?
NCT03886077 is a clinical study titled "Study of Hepatitis Eradication Receiving Protease Inhibitor Administration". This is a prospective, non-blinded cohort study that will assess the safety, tolerability, and antiviral efficacy of glecaprevir/pibrentasivir therapy given post-discharge to HCV-negative recipients of HCV infected donors. Patients who meet entry criteria will be enrolled while on the transplant wai...
What is the current status of trial NCT03886077?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2019-03-20. Estimated completion is 2024-12-31.
What conditions does trial NCT03886077 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Morality.
What interventions are being tested in trial NCT03886077?
The interventions under investigation include: glecaprevir/pibrentasivir (DRUG).
Who is sponsoring clinical trial NCT03886077?
This trial is sponsored by Sentara Norfolk General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03886077 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.